Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa Maria Diaz

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Molecular Therapy Oncolytics|July 13, 2018
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV<sup>POS</sup> CancersLukkana Suksanpaisan, Rong Xu, Mulu Z Tesfay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2025
The progressively exhausted T cell response to a poorly immunogenic model of HCC can be partially rescued by immune checkpoint blockade and is heavily suppressed by T cell responses to oncolytic virotherapyThanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2Rianna Vandergaast, Timothy Carey, Samantha Reiter, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Molecular Therapy Oncolytics|July 13, 2018
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV<sup>POS</sup> CancersLukkana Suksanpaisan, Rong Xu, Mulu Z Tesfay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2025
The progressively exhausted T cell response to a poorly immunogenic model of HCC can be partially rescued by immune checkpoint blockade and is heavily suppressed by T cell responses to oncolytic virotherapyThanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2Rianna Vandergaast, Timothy Carey, Samantha Reiter, et al.
Pageof 5